Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression

José M. Martinez-Navio, Sebastian P. Fuchs, Shara N. Pantry, William A. Lauer, Natasha N. Duggan, Brandon F. Keele, Eva G. Rakasz, Guangping Gao, Jeffrey D. Lifson, Ronald C. Desrosiers

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Although anti-retroviral drug therapy can suppress HIV viral replication, it is not a cure. Martinez-Navio et al. report the functional cure of the “Miami monkey,” in which long-term SHIV suppression was achieved after a single administration of adeno-associated viruses (AAVs) encoding broadly neutralizing antibodies. They also report that host-generated anti-antibodies can hamper the applicability of this approach.

Original languageEnglish (US)
Pages (from-to)567-575.e5
JournalImmunity
Volume50
Issue number3
DOIs
StatePublished - Mar 19 2019

Keywords

  • AAV vector
  • HIV broadly neutralizing antibodies
  • SHIV infection
  • adeno-associated virus
  • anti-drug antibodies
  • functional cure
  • gene therapy
  • immunotherapy
  • rhesus macaques
  • viral reservoir

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression'. Together they form a unique fingerprint.

  • Cite this

    Martinez-Navio, J. M., Fuchs, S. P., Pantry, S. N., Lauer, W. A., Duggan, N. N., Keele, B. F., Rakasz, E. G., Gao, G., Lifson, J. D., & Desrosiers, R. C. (2019). Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression. Immunity, 50(3), 567-575.e5. https://doi.org/10.1016/j.immuni.2019.02.005